Legal & General Group Plc Acquires 5,493 Shares of Jazz Pharmaceuticals PLC (JAZZ)
Legal & General Group Plc raised its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.4% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 231,838 shares of the specialty pharmaceutical company’s stock after buying an additional 5,493 shares during the period. Legal & General Group Plc owned approximately 0.39% of Jazz Pharmaceuticals PLC worth $36,051,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in JAZZ. US Bancorp DE boosted its stake in Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc purchased a new stake in Jazz Pharmaceuticals PLC during the first quarter worth approximately $205,000. Gargoyle Investment Advisor L.L.C. purchased a new stake in Jazz Pharmaceuticals PLC during the second quarter worth approximately $206,000. Finally, Janney Montgomery Scott LLC purchased a new stake in Jazz Pharmaceuticals PLC during the second quarter worth approximately $211,000. Institutional investors and hedge funds own 88.24% of the company’s stock.
Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 145.94 on Thursday. The stock’s 50 day moving average is $152.07 and its 200 day moving average is $148.41. The company has a market capitalization of $8.77 billion, a P/E ratio of 22.48 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 earnings per share. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/31/legal-general-group-plc-acquires-5493-shares-of-jazz-pharmaceuticals-plc-jazz.html.
A number of equities research analysts have recently commented on JAZZ shares. Wells Fargo & Company reiterated an “outperform” rating and set a $177.00 price target (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. BidaskClub cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price target on the stock in a report on Tuesday, June 6th. Piper Jaffray Companies reiterated an “overweight” rating and set a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Finally, Cowen and Company reiterated an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $180.96.
In other news, EVP Suzanne Sawochka Hooper sold 420 shares of Jazz Pharmaceuticals PLC stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $160.00, for a total transaction of $67,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $150.65, for a total value of $30,130.00. Following the transaction, the executive vice president now directly owns 22,223 shares of the company’s stock, valued at approximately $3,347,894.95. The disclosure for this sale can be found here. Insiders have sold a total of 7,917 shares of company stock worth $1,223,227 over the last 90 days. Insiders own 4.30% of the company’s stock.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.